Nuveen Asset Management, LLC Protagonist Therapeutics, Inc Transaction History

Nuveen Asset Management, LLC

$345 Billion
Q3 2024

A detailed history of Nuveen Asset Management, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 232,074 shares of PTGX stock, worth $10.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

232,074

Previous 373,992 37.95%

Holding current value

$10.2 Million

Previous $13 Million 19.52%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$33.72 - $47.33 $4.79 Million - $6.72 Million	-141,918 Reduced 37.95%	232,074 $10.4 Million
Q2 2024 Aug 09, 2024	SELL	$24.66 - $34.8 $7.5 Million - $10.6 Million	-304,209 Reduced 44.86%	373,992 $13 Million
Q1 2024 May 13, 2024	BUY	$21.79 - $32.15 $8.12 Million - $12 Million	372,782 Added 122.06%	678,201 $19.6 Million
Q4 2023 Feb 14, 2024	SELL	$14.05 - $23.44 $3.24 Million - $5.41 Million	-230,605 Reduced 43.02%	305,419 $7 Million
Q3 2023 Nov 14, 2023	SELL	$16.68 - $23.66 $6.67 Million - $9.46 Million	-399,937 Reduced 42.73%	536,024 $8.94 Million
Q2 2023 Aug 14, 2023	BUY	$18.02 - $29.36 $1.94 Million - $3.16 Million	107,490 Added 12.97%	935,961 $25.9 Million
Q1 2023 May 15, 2023	BUY	$10.78 - $25.38 $5.04 Million - $11.9 Million	467,757 Added 129.68%	828,471 $19.1 Million
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $163,171 - $247,638	22,170 Added 6.55%	360,714 $3.94 Million
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $4,495 - $6,698	572 Added 0.17%	338,544 $2.85 Million
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $239,051 - $864,107	33,860 Added 11.13%	337,972 $2.67 Million
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $1.5 Million - $2.32 Million	64,183 Added 26.75%	304,112 $2.35 Million
Q4 2021 Feb 14, 2022	BUY	$17.63 - $37.1 $1.35 Million - $2.85 Million	76,843 Added 47.12%	239,929 $1.85 Million
Q3 2021 Nov 12, 2021	SELL	$12.95 - $49.69 $41,945 - $160,945	-3,239 Reduced 1.95%	163,086 $1.26 Million
Q2 2021 Aug 16, 2021	BUY	$25.57 - $44.88 $552,951 - $970,530	21,625 Added 14.94%	166,325 $1.29 Million
Q1 2021 May 17, 2021	BUY	$19.02 - $31.15 $611,093 - $1 Million	32,129 Added 28.54%	144,700 $1.12 Million
Q4 2020 Feb 16, 2021	SELL	$18.49 - $25.13 $13,423 - $18,244	-726 Reduced 0.64%	112,571 $870,000
Q3 2020 Nov 16, 2020	BUY	$15.19 - $22.4 $342,154 - $504,559	22,525 Added 24.81%	113,297 $876,000
Q2 2020 Aug 14, 2020	SELL	$6.19 - $18.84 $51,383 - $156,390	-8,301 Reduced 8.38%	90,772 $701,000
Q1 2020 May 14, 2020	SELL	$5.4 - $9.22 $514,965 - $879,256	-95,364 Reduced 49.05%	99,073 $699,000
Q4 2019 Feb 14, 2020	BUY	$4.69 - $13.45 $205,919 - $590,535	43,906 Added 29.17%	194,437 $1.37 Million
Q3 2019 Nov 14, 2019	BUY	$9.41 - $16.56 $1.05 Million - $1.85 Million	111,656 Added 287.22%	150,531 $1.81 Million
Q2 2019 Aug 15, 2019	BUY	$8.98 - $12.96 $349,097 - $503,820	38,875 New	38,875 $470,000

Others Institutions Holding PTGX

# of Institutions

247

Shares Held

56.4M

Call Options Held

76.3K

Put Options Held

114K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.15B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Protagonist Therapeutics, Inc Transaction History